eMJA     The Medical Journal of Australia

Home | Issues | eMJA shop | My account | Classifieds | Contact | More... | Topics | Search   

For Debate

Should Australia lift its ban on low nitrosamine smokeless tobacco products?

Coral E Gartner and Wayne D Hall
MJA 2008; 188 (1): 44-46
Abstract
  • In Australia, 2.9 million people continue to smoke daily, and tobacco still accounts for 8% of disease burden.

  • Tobacco harm-reduction strategies, such as the use of Swedish snus, have been suggested as a way to further reduce this disease burden.

  • In Australia, the most dangerous tobacco products (cigarettes) are the least regulated, while oral tobacco products, including snus, cannot be sold legally.

  • Recent epidemiological modelling indicates that there are only small differences in life expectancy between smokers who quit and those who switch to snus.

  • There is a case on public health and ethical grounds for allowing inveterate smokers who want to reduce their health risks to access snus.

  • At a minimum, the recent increase in tax on smokeless tobacco should be reversed, and the ban on the commercial importation and supply of low nitrosamine smokeless tobacco should be reconsidered in light of the epidemiological evidence on its potential to reduce tobacco-related disease in smokers.

Home | Issues | eMJA shop | My account | Classifieds | More... | Contact | Topics | Search

The Medical Journal of Australia    eMJA  

©The Medical Journal of Australia 2007 www.mja.com.au PRINT ISSN: 0025-729X ONLINE ISSN: 1326-5377